



Dietary regulation of microRNA expression in colorectal cells

Karen Joy Humphreys

Bachelor of Medical Science

Bachelor of Nutrition and Dietetics (Honours)

Department of Gastroenterology and

Department of Nutrition and Dietetics

School of Medicine

Faculty of Health Science

Flinders University

A thesis submitted for the degree of

Doctor of Philosophy

2012

Table of Contents

List of Figures	viii
List of Tables	xii
List of Abbreviations	xiv
Summary	xix
Declaration	xxi
Publications and Presentations	xxii
Peer-reviewed Publications	xxii
Poster Presentations	xxii
Oral presentations	xxii
Acknowledgements	xxiii
Chapter 1. Introduction	1
1.1 Epigenetic modulation of gene expression.....	1
1.2 Development and progression of colorectal cancer.....	2
1.2.1 Epidemiology of colorectal cancer.....	2
1.2.2 Characteristics of colorectal cancer development.....	3
1.2.3 Genetic and epigenetic events in colorectal cancer development	5
1.2.4 Risk factors in colorectal cancer development	9
1.3 Diet and colorectal cancer	10
1.3.1 Dietary influences on the colon.....	10
1.3.2 Butyrate and colorectal cancer	13
1.4 microRNAs and colorectal cancer	14
1.4.1 Definition and discovery of microRNAs	15
1.4.2 microRNA biogenesis and mechanism of action.....	16
1.4.3 microRNAs in development and disease	19
1.4.4 microRNAs in colorectal cancer.....	20
1.5 Diet and microRNA regulation	29
Chapter 2. Aims	35

TABLE OF CONTENTS

2.1 General hypotheses and aims.....	35
2.2 Chapter 4 aim	35
2.3 Chapter 5 aim	35
2.4 Chapter 6 aim	36
2.5 Chapter 7 aim	36
2.6 Chapter 8 aim	36
Chapter 3. Materials and Methods	37
3.1 <i>In vitro</i> experimental methods.....	37
3.1.1 Cell culture	37
3.1.2 Cell treatments.....	38
3.1.3 RNA extraction and quantification	39
3.1.4 Protein extraction and quantification.....	40
3.1.5 Microarray analysis.....	41
3.1.6 Relative quantitation real-time RT-PCR.....	41
3.1.7 Western blot analysis	43
3.1.8 Transfection with microRNA mimics, target protectors and small interfering RNAs (siRNAs).....	44
3.1.9 Real-time cell growth analysis	45
3.1.10 microRNA target prediction	45
3.1.11 Chromatin immunoprecipitation.....	46
3.1.12 Statistical analysis	51
3.2 <i>In vivo</i> experimental methods – High red meat and resistant starch trial in humans.....	52
3.2.1 Study details	52
3.2.2 Objectives and hypotheses	52
3.2.3 Participant inclusion and exclusion criteria.....	53
3.2.4 Recruitment	53
3.2.5 Sample size determination	53
3.2.6 Randomisation procedure.....	53

TABLE OF CONTENTS

3.2.7 Interventions.....	54
3.2.8 Outcomes.....	55
3.2.9 microRNA and target gene mRNA analysis of rectal biopsies	58
3.2.10 Maintenance of records	58
3.2.11 Statistical methods	58
3.3 Reagents and equipment used for experiments.....	60
Chapter 4. Butyrate alters microRNA expression in colorectal cancer cell lines	67
4.1 Introduction.....	67
4.1.1 Effect of butyrate on gene expression in colorectal cancer cells	67
4.2 Aim	75
4.3 Methods overview	75
4.4 Results	75
4.4.1 Proliferation of colorectal cancer cell lines with butyrate treatment... 75	
4.4.2 microRNA microarray analysis of butyrate-treated colorectal cancer cell lines.....	77
4.4.3 Real-time RT-PCR validation of microRNAs with butyrate-induced expression changes in colorectal cancer cell lines.....	82
4.4.4 Butyrate-induced microRNA expression changes in butyrate-resistant versus standard colorectal cancer cell lines.....	88
4.4.5 Ingenuity pathway analysis of microRNAs with butyrate-induced expression changes	93
4.5 Discussion.....	97
Chapter 5. HDI treatment reduces miR-17-92 cluster expression and increases expression of target genes	102
5.1 Introduction.....	102
5.1.1 Histone deacetylase inhibitors.....	102
5.1.2 The miR-17-92 cluster.....	111
5.2 Aims.....	116
5.3 Methods overview	116
5.4 Results	116

TABLE OF CONTENTS

5.4.1 Proliferation of colorectal cancer cell lines with HDI treatment.....	116
5.4.2 Real-time RT-PCR of miR-17-92 changes in colorectal cancer cells treated with butyrate and other HDIs	117
5.4.3 Expression of miR-17-92 validated target genes and regulators in colorectal cancer cells treated with butyrate.....	122
5.4.4 miR-17-92 microRNAs and target genes in colorectal cancer cells and normal human rectal mucosa.....	127
5.5 Discussion.....	130
Chapter 6. Treatment with HDIs reveals competing roles for miR-17-92 cluster members	136
6.1 Introduction.....	136
6.1.1 microRNA mimics.....	136
6.1.2 Validation of microRNA targets.....	138
6.2 Aims.....	141
6.3 Methods overview	141
6.4 Results	142
6.4.1 Proliferation of colorectal cancer cell lines following manipulation of mir-17-92 cluster members during HDI treatment.....	142
6.4.2 Expression of miR-17-92 validated target genes in colorectal cancer cells following transfection with miR-19 (a and b), 17, 20a, and 92a during HDI treatment	146
6.4.3 Expression of miR-18a predicted target genes in colorectal cancer cells following transfection with miR-18a during HDI treatment.....	149
6.4.4 Validation of <i>NEDD9</i> and <i>CDK19</i> as miR-18a targets	153
6.4.5 Confirmation of <i>NEDD9</i> and <i>CDK19</i> as genes that influence proliferation.....	157
6.5 Discussion.....	159
Chapter 7. Butyrate alters miR-17-92 cluster transcription via specific histone modifications	170
7.1 Introduction.....	170
7.1.1 Histone modifications and chromatin remodelling	170

TABLE OF CONTENTS

7.1.2 Detection of histone modifications at the <i>MIR17HG</i> gene locus.....	177
7.2 Aims.....	178
7.3 Methods overview	178
7.3.1 Cycloheximide treatment.....	178
7.3.2 ChIP analysis of activating histone methylation and acetylation marks	179
7.4 Results	181
7.4.1 Real-time RT-PCR of miR-17-92 changes in colorectal cancer cells treated with butyrate, in the presence or absence of cycloheximide.....	181
7.4.2 ChIP analysis of butyrate-induced H3 histone modifications – preparatory experiment (<i>MIR17HG</i> primer design)	185
7.4.3 ChIP analysis of butyrate-induced H3 histone modifications – preparatory experiment (micrococcal nuclease optimisation)	187
7.4.4 ChIP analysis of butyrate-induced H3 histone modifications at the <i>MIR17HG</i> locus	189
7.5 Discussion.....	197
Chapter 8. Red meat and resistant starch alter microRNA expression in rectal tissue of healthy human volunteers	204
8.1 Introduction.....	204
8.1.1 Dietary fibre and resistant starch.....	204
8.1.2 Red meat and processed meat.....	208
8.1.3 Resistant starch may attenuate red-meat induced damage.....	210
8.2 Aim	211
8.3 Methods overview	211
8.4 Results	213
8.4.1 Trial description and participant demographics	213
8.4.2 Body weight and dietary intake assessed using three-day weighed food records.....	216
8.4.3 SCFA levels in faecal samples	217

TABLE OF CONTENTS

8.4.4 Real-time RT-PCR analysis of microRNA levels in rectal biopsy samples.....	220
8.4.5 Real-time RT-PCR analysis of miR-17-92 target gene mRNA levels in rectal biopsy samples	224
8.5 Discussion.....	226
Chapter 9. General conclusions	231
9.1 Thesis summary	231
9.1.1 Butyrate alters microRNA expression in colorectal cancer cell lines.....	232
9.1.2 HDI treatment reduces miR-17-92 cluster expression and increases expression of target genes in colorectal cancer cells	232
9.1.3 Treatment with HDIs reveals competing roles for miR-17-92 cluster members	234
9.1.4 Butyrate alters miR-17-92 cluster transcription via specific histone modifications at the locus of <i>MIR17HG</i> , the miR-17-92 host gene.....	235
9.1.5 Red meat and resistant starch alter miR-17-92 cluster expression in rectal mucosa cells of healthy human volunteers	236
9.2 Future directions and applications	237
9.3 Conclusions	243
Appendix 1 – Preliminary experiments showing butyrate-induced microRNA expression changes	245
Appendix 2 – Ingenuity Pathway Analysis of miR-18a predicted target genes ..	246
Appendix 3 – Period effect analysis for high red meat and resistant starch trial	249
References.....	251

List of Figures

Figure 1.1 miRNA biogenesis pathway	18
Figure 4.1: Proliferation of HT29 and HCT116 cells after 48 h of butyrate treatment. .	76
Figure 4.2: Microarray analysis of miRNA expression in HT29 cells after 48 h of butyrate treatment – volcano plot.	78
Figure 4.3: Real-time RT-PCR analysis of miRNA levels in HT29 cells for miRNAs identified by the microarray experiment as being up-regulated with 48 h butyrate treatment.	85
Figure 4.4: Real-time RT-PCR analysis of miRNA levels in HCT116 cells for miRNAs identified by the microarray experiment as being up-regulated with 48 h butyrate treatment.	85
Figure 4.5: Real-time RT-PCR analysis of miRNA levels in HT29 cells for miRNAs identified by microarray as being down-regulated with 48 h butyrate treatment.	86
Figure 4.6: Real-time RT-PCR analysis of miRNA levels in HCT116 cells for miRNAs identified by microarray as being down-regulated with 48 h butyrate treatment.	87
Figure 4.7: Proliferation of standard and butyrate-resistant HT29 and HCT116 cells after 48 h of butyrate treatment.....	90
Figure 4.8: Real-time RT-PCR analysis of miRNAs levels for miRNAs identified by microarray as being down-regulated with 48 h butyrate treatment (miR-17-92 cluster) – comparison between standard HT29 and HT29-BR cells.....	91
Figure 4.9: Real-time RT-PCR analysis of miRNAs levels for miRNAs identified by microarray as being down-regulated with 48 h butyrate treatment (miR-17-92 cluster) – comparison between standard HCT116 and HCT116-BR cells.....	92
Figure 4.10: First top IPA network associated with miRNAs showing butyrate-induced expression changes, displaying predicted miRNA and gene interactions.....	95
Figure 4.11: Second top IPA network associated with miRNAs showing butyrate-induced expression changes, displaying predicted miRNA and gene interactions.....	96
Figure 5.1: Structure of the human miR-17-92 cluster and its paralogs, miR-106a-363 and miR-106b-25.	114
Figure 5.2: Transcriptional regulation and target mRNAs of the miR-17-92 cluster	115
Figure 5.3: Proliferation of HT29 and HCT116 cells after 48 h of butyrate or SAHA treatment.	118
Figure 5.4: Real-time RT-PCR validation of miR-17-92 cluster changes in HT29 cells after 48 h of butyrate, TSA or SAHA treatment.....	119

LIST OF FIGURES

Figure 5.5: Real-time RT-PCR validation of miR-17-92 cluster changes in HCT116 cells after 48 h of butyrate, TSA or SAHA treatment.....	120
Figure 5.6: Changes in miR-17-92 cluster target gene mRNA levels in HT29 and HCT116 cells after 48 h of butyrate treatment: Real-time RT-PCR.	123
Figure 5.7: Changes in miR-17-92 cluster target gene protein levels in HT29 cells after 48 h of butyrate treatment: Western blot.	124
Figure 5.8: Changes in miR-17-92 cluster target gene protein levels in HCT116 cells after 48 h of butyrate treatment: Western blot.....	125
Figure 5.9: Changes in mRNA levels of transcription factors that regulate <i>MIR17HG</i> (the miR-17-92 host gene) in HT29 and HCT116 cells after 48 h of butyrate treatment: Real-time RT-PCR.	126
Figure 5.10: Comparison of miR-17-92 miRNA levels in untreated control CRC cells, 5 mM butyrate-treated CRC cells and normal human rectal mucosa.....	128
Figure 5.11: Comparison of <i>CDKN1A</i> , <i>PTEN</i> , and <i>BCL2L1</i> mRNA levels in untreated control CRC cells, 5 mM butyrate-treated CRC cells and normal human rectal mucosa.....	129
Figure 6.1: Proliferation of HT29 cells after transfection with miR-17-92 miRNAs and treatment with butyrate or control medium for 48 h	144
Figure 6.2: Proliferation of HT29 and HCT116 cells after transfection with miR-19 (a and b), miR-18a, miR-17-92 (minus miR-18a), or all miR-17-92 miRNAs and treatment with butyrate, SAHA or control medium for 48 h	145
Figure 6.3: Target gene expression in HT29 cells after transfection with miR-17-92 miRNAs and treatment with butyrate or control medium	147
Figure 6.4: Target gene expression in HCT116 cells after transfection with miR-17-92 miRNAs and treatment with butyrate or control medium	148
Figure 6.5: Target gene mRNA levels in HT29 and HCT116 cells after transfection with miR-18a and treatment with butyrate or control medium.....	150
Figure 6.6: Target gene protein levels in HT29 cells after transfection with miR-18a and treatment with butyrate.....	151
Figure 6.7: Target gene protein levels in HCT116 cells after transfection with miR-18a and treatment with butyrate	152
Figure 6.8: Schematic of the miR-18a seed region that targets the <i>NEDD9</i> 3'UTR at four sites, with designed target protector details.....	154
Figure 6.9: Schematic of the miR-18a seed region that targets the <i>CDK19</i> 3'UTR at three sites, with designed target protector details	155

LIST OF FIGURES

Figure 6.10: <i>NEDD9</i> and <i>CDK19</i> expression in butyrate-treated HT29 and HCT116 cells after co-transfection with miR-18a and specific target protectors.....	156
Figure 6.11: Effect of <i>NEDD9</i> and <i>CDK19</i> RNA interference on proliferation of HT29 and HCT116 cells	158
Figure 7.1: Possible post-translational histone modifications on N-terminal and C-terminal regions of the four core histones.	176
Figure 7.2: Experimental outline of the chromatin immunoprecipitation (ChIP) procedure used to analyse histone acetylation and methylation patterns at the <i>MIR17HG</i> locus.....	180
Figure 7.3: Real-time RT-PCR validation of miR-17-92 cluster changes in HT29 cells after 48 h of butyrate treatment, in the absence or presence of cycloheximide	183
Figure 7.4: Real-time RT-PCR validation of miR-17-92 cluster changes in HCT116 cells after 48 h of butyrate treatment, in the absence or presence of cycloheximide	184
Figure 7.5: Location of primer pairs for amplification of the <i>MIR17HG</i> gene and upstream region, including the proximal promoter region and TSS.....	186
Figure 7.6: Agarose gel electrophoresis analysis of HT29 chromatin digestion optimisation using increasing concentrations of Micrococcal Nuclease	188
Figure 7.7: Agarose gel electrophoresis analysis of chromatin digestion of control and butyrate-treated HT29 cells, using optimised concentration of Micrococcal Nuclease	192
Figure 7.8: Real-time qPCR analysis of chromatin immunoprecipitation using Human <i>RPL30</i> Exon 3 control primer set, for control and butyrate-treated HT29 cells.....	193
Figure 7.9: Real-time qPCR analysis of chromatin immunoprecipitation to detect histone acetylation and methylation levels at <i>MIR17HG</i> locus for control and butyrate-treated HT29 cells.....	194
Figure 7.10: Summary of changes in histone acetylation and methylation distribution surrounding <i>MIR17HG</i> in butyrate-treated HT29 cells compared with control cells...	195
Figure 7.11: Summary of changes in total histone H3 distribution surrounding <i>MIR17HG</i> in butyrate-treated HT29 cells compared with control cells	196
Figure 8.1: High red meat and resistant starch cross-over trial intervention and data collection flow diagram.....	213
Figure 8.2: CONSORT diagram of participant flow for the high red meat and resistant starch trial.....	215
Figure 8.3: Faecal butyrate, acetate, propionate, and total SCFA levels of participants in the high red meat and resistant starch trial	219
Figure 8.4: Real-time RT-PCR of miR-17-92 cluster levels in rectal biopsies from participants in the high red meat and resistant starch trial	222

LIST OF FIGURES

Figure 8.5: Real-time RT-PCR of miR-16 and miR-21 in rectal biopsies from participants in the high red meat and resistant starch trial	223
Figure 8.6: Real-time RT-PCR of miR-17-92 target gene expression in rectal biopsies from participants in the high red meat and resistant starch trial	225
Figure 9.1: Proposed mechanism by which differing levels of miR-17-92 cluster miRNAs in normal cells, CRC cells, and CRC cells with HDI treatment alter identified target genes and cell outcomes.	240
Figure A1.1: Real-time RT-PCR analysis of miR-17-92 levels in HT29 and HCT116 cells with 48 h butyrate treatment.	245
Figure A3.1: Groups-by-periods plot for faecal butyrate levels of participants in the high red meat and resistant starch trial.....	249
Figure A3.2: Groups-by-periods plot for miR-17-92 cluster miRNA levels in rectal biopsies of participants in the high red meat and resistant starch trial.....	250

List of Tables

Table 1.1: Studies reporting altered miRNA expression in colorectal cancer cells from human tumour tissue samples.....	23
Table 1.2: Studies reporting altered miRNA expression in <i>in vivo</i> and <i>in vitro</i> cancer models in response to treatment with a dietary component	33
Table 3.1: High red meat and resistant starch trial details	52
Table 3.2: High red meat and resistant starch trial participant inclusion and exclusion criteria	53
Table 3.3: High red meat and resistant starch trial intervention and data collection flow chart	58
Table 3.4: Chemicals and reagents	60
Table 3.5: Equipment and software	61
Table 3.6: Primers and oligonucleotides.....	62
Table 3.7: Antibodies.....	65
Table 3.8: Buffers and solutions	66
Table 4.1: Microarray studies showing the effect of butyrate on gene expression using human colorectal cell lines.....	71
Table 4.2: Microarray analysis of miRNA expression in HT29 cells after 48 h of butyrate treatment – list of differentially expressed miRNAs	79
Table 4.3: <i>P</i> values showing the significant decrease in miR-17-92 and miR-106a-363 cluster mature miRNA levels in standard HT29 and HCT116 treated with 5 mM butyrate for 48 h as detected by real-time RT-PCR.....	84
Table 4.4 <i>P</i> values showing the significant decrease in miR-17-92 cluster mature miRNA levels in butyrate-resistant HT29 and HCT116 treated with 5 mM butyrate for 48 h as detected by real-time RT-PCR.....	89
Table 4.5: Top IPA networks associated with miRNAs showing butyrate-induced expression changes	94
Table 4.6: Top IPA diseases and disorders associated with miRNAs showing butyrate-induced expression changes	94
Table 4.7: Top IPA molecular and cellular functions associated with miRNAs showing butyrate-induced expression changes.....	94
Table 5.1: Classical histone deacetylases (HDACs)	109
Table 5.2: Known histone deacetylase (HDAC) inhibitors	110

LIST OF TABLES

Table 5.3: Changes in miR-17-92 and miR-106a-363 cluster mature miRNA levels in HT29 and HCT116 cells treated with butyrate, TSA or SAHA for 48 h as detected by real-time RT-PCR.	121
Table 8.1: Usual dietary intake of study participants in the high red meat and resistant starch trial, based on food frequency questionnaire data (Cancer Council Victoria 2005)	214
Table 8.2: Dietary intake of study participants in the high red meat and resistant starch trial during each diet period, based on three-day weighed food records.....	216
Table 8.3: Faecal butyrate levels for high red meat and high red meat + resistant starch intervention diets, with analysis of variance for treatment effect, period effect and carry-over effect	218
Table 8.4: miR-17-92 cluster miRNA levels in rectal biopsies assessed using real-time RT-PCR for high red meat and high red meat + resistant starch intervention diets, with analysis of variance for treatment effect, period effect and carry-over effect	221
Table A2.1: Top IPA networks associated with potential miR-18a target genes	246
Table A2.2: Top IPA diseases and disorders associated with potential miR-18a target genes	246
Table A2.3: Top IPA molecular and cellular functions associated with potential miR-18a target genes	247
Table A2.4: List of potential miR-18a target genes, identified using the intersection of prediction programs in miRGen.....	247

List of Abbreviations

Ac	acetylation
ACTB	beta actin
ACVR2	activin type 2 receptors
AGO2	argonaute-2
AKT (PKB)	v-akt murine thymoma viral oncogene homolog 1
ANOVA	analysis of variance
APC	adenomatous polyposis coli
APS	ammonium persulfate
Arg	arginine
BAX	BCL2-associated X protein
BCL2L11 (Bim)	BCL2-like 11 (apoptosis facilitator)
BR	butyrate-resistant
BRAF	v-Raf murine sarcoma viral oncogene homolog B1
C13ORF25	C13 open reading frame 25
CAS	cellular apoptosis susceptibility
CCDC88A	coiled-coil domain containing 88A
CCND1	cyclin D1
CCNE1	cyclin E1
CDK19 (CDC2L6)	cyclin-dependent kinase 19
CDK8	cyclin-dependent kinase 8
CDKN1A (p21)	cyclin-dependent kinase inhibitor 1A
CDKN2A	cyclin-dependent kinase inhibitor 2A
cDNA	complementary DNA
CDX2	caudal type homeobox 2
ChIP	chromatin immunoprecipitation
CHX	cycloheximide
CIMP	CpG island methylator phenotype
CIN	chromosomal instability
CRC	colorectal cancer
CSIRO	Commonwealth Scientific and Industrial Research Organisation
CTGF	connective tissue growth factor
CTNNB1	catenin (cadherin-associated protein), beta 1
DALY	disability-adjusted life year

LIST OF ABBREVIATIONS

DGCR8	DiGeorge syndrome critical region gene 8
DMSO	dimethyl sulfoxide
DNA	deoxyribonucleic acid
DNMT1	DNA (cytosine-5-)-methyltransferase 1
DNMT3A	DNA (cytosine-5-)-methyltransferase 3 alpha
DNMT3B	DNA (cytosine-5-)-methyltransferase 3 beta
dsRNA	double stranded RNA
DTT	dithiothreitol
E2F	E2F transcription factor family
E2F1	E2F transcription factor 1
E2F2	E2F transcription factor 2
E2F3	E2F transcription factor 3
ECL	enhanced chemiluminescence
EDTA	ethylenediaminetetraacetic acid
EGR2	early growth response 2
EMAST	elevated microsatellite instability at selected tetranucleotide repeats
EPIC	European Prospective Investigation into Cancer and Nutrition
ESR1	estrogen receptor 1
FAP	familial adenomatous polyposis
FBXW7	F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase
FDA	US Food and Drug Administration
FOS	v-fos FBJ murine osteosarcoma viral oncogene homolog
FSANZ	Food Standards Australia New Zealand
GAB1	GRB2-associated binding protein 1
GAB2	GRB2-associated binding protein 2
GADD45A	growth arrest and DNA-damage-inducible, alpha
H1/H5	histone 1/ histone 5
H2A and 2B	histone 2A and 2B
H3	histone 3
H4	histone 4
HAT	histone acetyltransferase
HER2 (ERBB2)	human epidermal growth factor receptor 2
HDAC	histone deacetylase
HDI	histone deacetylase inhibitor

LIST OF ABBREVIATIONS

HDM	histone demethylases
His	histidine
HMT	histone methyltransferase
HNPCC	hereditary nonpolyposis colorectal cancer
hnRNPA1	heterogeneous nuclear ribonucleoprotein A1
HRAS	v-Ha-ras Harvey rat sarcoma viral oncogene homolog
IgG	immunoglobulin G
IP	immunoprecipitation
IPA	Ingenuity Pathway Analysis
JARID1B	histone demethylase jumonji, AT rich interactive domain 1B
K	lysine
KRAS	v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
LIN28A	lin-28 homolog A
Lys	lysine
MAP	mitogen-activated protein
MAPK7 (ERK5)	mitogen-activated protein kinase 7
MAPK12	mitogen-activated protein kinase 12
MCC	mutated in colorectal cancers
me	methylation
me2	di-methylation
me3	tri-methylation
MGMT	O6-methylguanine-DNA methyltransferase
MIR17HG	miR-17-92 cluster host gene
miRNA	microRNA
MLH1	DNA mismatch repair protein MLH1 (MutL protein homolog 1)
MLH2	DNA mismatch repair protein MLH2 (MutL protein homolog 2)
MSH2	mutS homolog 2
MSH3	mutS homolog 3
MSH6	mutS homolog 6
MSI	microsatellite instability
MSS	microsatellite stable
MYB	v-myb myeloblastosis viral oncogene homolog
MYC (C-MYC)	myelocytomatosis oncogene
NC	negative control
NEDD9 (HEF1)	neural precursor cell expressed, developmentally down-regulated

LIST OF ABBREVIATIONS

NF- κ B	nuclear factor kappa-light-chain-enhancer of activated B cells
NHMRC	National Health and Medical Research Council
NR	not reported
NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog
NRM	normal rectal mucosa
NSP	non-starch polysaccharide
O6CMG	O6-carboxymethylguanine
O6MeG	O6-methyl-2-deoxyguanosine
PACT	protein activator of PKR
PBS	phosphate buffered saline
PcG	polycomb group
PDCD4	programmed cell death 4
RHOB	ras homolog family member B
PI3K	phosphatidylinositol 3-kinases
PIC	protease inhibitor cocktail
PIK3CA	phosphoinositide-3-kinase, catalytic, alpha polypeptide
PMS2	postmeiotic segregation increased 2
PMSF	phenylmethylsulfonyl fluoride
pre-miRNA	precursor miRNA
pri-miRNA	primary miRNA
PTEN	phosphatase and tensin homolog
RISC	RNA-induced silencing complex
RM	red meat
RNA	ribonucleic acid
RNAi	RNA interference
RNU6B	U6B small nuclear RNA
RPL30	ribosomal protein L30
RS	resistant starch
RTCA	real-time cell analysis
RT-PCR	reverse transcription polymerase chain reaction
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SAHA	suberoylanilide hydroxamic acid
SCFA	short-chain fatty acid
SD	standard deviation
SEM	standard error of the mean
shRNA	short hairpin RNA

LIST OF ABBREVIATIONS

siRNA	small interfering RNA
SIS (PDGFB)	platelet-derived growth factor beta polypeptide
SMAD2	SMAD family member 2
SMAD3	SMAD family member 3
SMAD4	SMAD family member 4
SP1	Sp1 transcription factor
SP3	Sp3 transcription factor
TBS	tris-buffered saline
TCF4	transcription factor 4
TEMED	tetramethylethylenediamine
TGFBIIIR	transforming growth factor beta, receptor type II
TNM	Tumour Node Metastasis (TNM) Classification of Malignant Tumours
TP	target protector
TP53	tumour protein p53
TPM1	tropomyosin 1
TRBP	human immunodeficiency virus transactivating response RNA-binding protein
TRxG	trithorax group
TS	thymidylate synthase
TSA	trichostatin A
TSP1	thrombospondin-1
TSS	transcription start site
TXNIP	thioredoxin-interacting protein
UTR	untranslated region
WCRF	World Cancer Research Fund
WNT	wnt signalling protein
XPO5	exportin 5
YLL	years of life lost

Summary

Colorectal cancer (CRC) development is associated with epigenetic modifications, including DNA methylation changes, altered histone modification patterns, and dysregulated microRNA (miRNA) expression. While some dietary compounds can alter colorectal cell behaviour through epigenetic mechanisms, their role in modifying miRNA expression in CRC cells and normal colorectal tissue has been less studied. The diet-derived compound butyrate, with its known role in histone modification, is a plausible candidate for altering miRNA expression. This study examined dietary regulation of miRNA expression in colorectal cells, and explored the role of butyrate and other histone deacetylase inhibitors (HDIs) in modulating CRC risk through altered miRNA expression. The down-stream consequences of these miRNA changes, and the roles of miRNAs in the context of the anti-proliferative effects of HDIs, were determined. In addition to exploring the action of butyrate, a potentially protective dietary component, the study also investigated whether factors that possibly increase CRC risk, such as high red meat intake, alter miRNA expression.

In vitro, butyrate and other HDIs altered levels of some miRNAs that are dysregulated in CRC, including the oncogenic miR-17-92 miRNA cluster which is over-expressed in CRC. Butyrate decreased miR-17-92 miRNA levels in CRC cells, with a corresponding increase in expression of miR-17-92 targets, including cell cycle inhibitors and pro-apoptotic genes. Mechanisms for this decrease included changes in regulators of miR-17-92 host gene transcription, and altered histone acetylation and methylation patterns centred around the transcription start site and promoter of the miR-17-92 host gene. Decreased miR-17-92 expression may be partly responsible for the anti-proliferative effects of HDIs, with introduction of miR-17-92 cluster miRNA mimics reversing this effect and decreasing target gene transcript levels. Of the cluster members, miR-19a and miR-19b were primarily responsible for promoting proliferation, while in a novel finding, miR-18a acted in opposition to other members to decrease growth. Two pro-proliferative genes, *NEDD9* and *CDK19*, were identified as novel miR-18a targets. This study presents the first evidence of competing roles for miR-17-92 cluster members, in the context of HDI-induced changes in CRC. miR-18a may play a homeostatic role in containing the oncogenic effects of the entire cluster, but may be selectively decreased in CRC compared with other cluster members.

SUMMARY

In addition to the capacity of butyrate to reverse the dysregulation of miR-17-92 miRNAs in CRC cells *in vitro*, this action was demonstrated with resistant starch supplementation *in vivo*, in rectal biopsies from healthy human volunteers exposed to high red meat levels. High red meat intake raised levels of miRNAs with oncogenic potential, particularly miR-17-92 cluster miRNAs and miR-21. Resistant starch supplementation raised faecal butyrate concentrations, and decreased miR-17-92 cluster miRNAs to baseline levels. *In vivo* modulation of miRNAs in colorectal cells by dietary compounds has not previously been demonstrated in humans. Regulation of miRNA expression demonstrates a plausible mechanism to explain some of the chemoprotective effects of butyrate, and potentially carcinogenic properties of other dietary components. Understanding how dietary compounds alter miRNA expression, and how miRNAs modulate the action of HDIs, may provide new opportunities for CRC therapies and prevention strategies.

Declaration

I certify that this thesis does not incorporate without acknowledgment any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Karen J Humphreys

Publications and Presentations

Peer-reviewed Publications

Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. *Molecular Carcinogenesis*. 5 February 2012. [Epub ahead of print].

Poster Presentations

Humphreys KJ, Le Leu RK, Cobiac L, Michael MZ. Butyrate alters microRNA expression in colorectal cells. 31st Lorne Genome Conference, Mantra Erskine Resort, Lorne, Victoria, Australia, 14 – 16 February 2010.

Humphreys KJ, Le Leu RK, Cobiac L, Michael MZ. Butyrate alters microRNA expression in colorectal cells. MicroRNAs and Non-Coding RNAs and Cancer Keystone Symposia Conference, Fairmont Banff Springs, Banff, Alberta, Canada, 11 – 16 February 2011.

Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Epigenetics 2012 4th Australian Scientific Conference, the National Wine Centre of Australia, Adelaide, South Australia, Australia, 7 – 9 May 2012. **Best conference poster prize.**

Oral presentations

Humphreys KJ, Le Leu RK, Cobiac L, Michael MZ. Butyrate alters microRNA expression in colorectal cells. Australian Society for Medical Research Annual Scientific Meeting, the Entertainment Centre, Adelaide, South Australia, Australia, 9 June 2010.

Various presentations at the Flinders Centre for Innovation in Cancer annual research days, Adelaide RNA special interest group meetings, and the Flinders Clinical and Molecular Medicine cluster seminar series.

Acknowledgements

I would like to sincerely thank my PhD supervisors for their advice and support throughout my PhD. I would particularly like to thank Dr Michael Michael for allowing me to undertake research in his laboratory, and for passing on his expert knowledge in the field of miRNAs. I would like to thank Dr Richard Le Leu for giving me the opportunity to be an investigator in the human dietary intervention trial, and Professor Lynne Cobiac for providing assistance on the dietary aspects of my project. Special thanks go to all my supervisors for the time they have given me during my PhD and during the final production of this thesis.

I would also like to thank Professor Graeme Young for his vision and commitment to enabling diet and colorectal cancer research at Flinders University. I am grateful to the Flinders Foundation and the NHMRC for funding during my PhD research.

My laboratory colleagues also deserve thanks for the support they have provided over my PhD, and I am particularly grateful to Letitia Pimlott and Veronika Bandara for their advice and helpful conversations.

I would like to thank Mark Van der Hoek and Rosalie Kenyon from the Adelaide microarray facility for assisting with the miRNA microarray, and researchers at CSIRO for sharing ideas and material. Dr Leah Cosgrove and Dr Kim Fung generously provided the butyrate-resistant cell lines, and collaborators at CSIRO involved in the human dietary intervention trial kindly allowed me to use the collected tissue for miRNA specific investigations.

Finally, a very large thank you goes to my family and friends for their love and support through my PhD journey. Thank you to Dave Mutton for all his support and for enabling me to complete my PhD. Thank you to my mum and dad for always being there to encourage me and provide assistance, and for inspiring me to pursue a career in science.